Skip to main content
 

Profile

Brian Gilger, DVM, MS, Dipl. ACVO, Dipl. ABT

Professor, Ophthalmology

Contact:

brian_gilger@ncsu.edu
Office: 919.513.1273
Lab: Ocular Immunology, Toxicology, and Drug Delivery
Lab Phone: 919.513.1273

Dr. Brian Gilger is a native of Akron, Ohio, USA. After an internship and residency in ophthalmology, he joined The Ohio State University as an Assistant Professor of Ophthalmology in 1992. In October of 1995, Dr. Gilger joined the faculty at North Carolina State University College of Veterinary Medicine as an Associate Professor of Ophthalmology and is now a Professor of Ophthalmology. Dr. Gilger is particularly interested in ocular diseases of horses and is the editor and author of three editions of the textbook, Equine Ophthalmology. He has over 130 peer reviewed scientific publications, over 30 book chapters, and has research interests in ocular drug delivery, immunology, pharmacology, and toxicology.

EDUCATION
Doctor of Veterinary Medicine, The Ohio State University; 1987
Internship, The Animal Medical Center, NY, NY; 1987-88
Residency in Ophthalmology, Auburn University; 1989-1992
Masters of Science, Auburn University; 1992
Affiliations
American Veterinary Medical Association, Member, 1987–present
Association for Research in Vision and Ophthalmology, Member, 1989–present
Fellow, 2016 - present
American College of Veterinary Ophthalmologists, Diplomate and Member, 1993–present
International Equine Ophthalmology Consortium, Member, 2009-present
North Carolina Veterinary Medical Association, Member, 1995 – present
American Society of Toxicology (SOT); 2013 – present
Councilor - Ocular Toxicology Specialty Section, 2014 – present
American Board of Toxicology, Diplomate, 2008-present
Certifications
Diplomate, American College of Veterinary Ophthalmologists
Diplomate, American Board of Toxicology
Biological Barriers, Immunology, Pharmacology
Ocular immunology
Ocular inflammation
Ocular toxicology
Ocular pharmacology
Sustained ocular drug delivery.

In the Laboratory of Ocular Immunology, Toxicology, and Drug Delivery, we study the pathogenesis of ocular immunologic and inflammatory disorders and have developed innovative methods to treat these potentially blinding diseases. We have been especially interested in the study of ocular toxicology and pharmacology of several medications. We study the two main causes of blindness in horses in the southern United States, equine recurrent uveitis and fungal keratitis. We are also interested in studying these naturally-occurring diseases, since they are models of common human diseases.

We have extensively explored methods to deliver therapeutic levels of medications to the eye for extended periods of time using micro-implant and sustained release injection technology. We are developing and evaluating innovative thermosensitive polymers for periocular and intraocular injection.

We are also interested in evaluating innovative methods for immunomodulation of the eye, including stem-cell therapy and gene therapy, for treatment of diseases such as uveitis, dry eye, immune-mediated keratitis, and inflammatory diseases of the retina. We are collaborating with the laboratories of Dr. Lauren Schnabel (NCSU), Jonathan Fogle (NCSU), and Matt Hirsch (UNC).
CLINICAL STUDIES
  • (2016) AAV gene therapy for MPS1-associated corneal blindness.Vance M, Llanga T, Bennett W, Woodard K, Murlidharan G, Chungfat N, Asokan A, Gilger B Kurtzberg J, Samulski J, Hirsch M. | Scientific Reports 2016;6:22131. doi: 10.1038/srep22131. PMID: 26899286
  • (2016) Sustained release protein therapeutics from subcutaneous thermosensitive biocompatible and biodegradable pentablock co-polymers.Schaefer E, Walsh M, Abbaraju S, Amin R, Salmon J, Weiss S, Grau U, Velagaleti P, Gilger B. | J Drug Delivery 2016 (Submitted)
  • (2016) Cytokine profiles in horses with uveitis measured using multiplex bead immunoassay analysis.Curto EM, Gilger BC. | Vet Immunol Immunopathol 2016 (in preparation)
  • (2016) Optimization of Aqueous Nanomicellar Resolvin E1 Analog (RX-10045) Topical Drop for Ocular Delivery.Cholkar K, Gilger BC, Mitra A. | J Ocular Pharm Therapeutics 2016 Feb 10;498(1-2):326-34. doi: 10.1016/j.ijpharm.2015.12.037
  • (2015) Phacoemulsification and aspiration for cataract management in a dollar sunfish, Lepomis marginatus (Holbrook) a case report.Adamovicz L, Gilger BC, Lewbart G. | Journal of Fish Diseases 2015 Dec;38(12):1089-92. doi: 10.1111/jfd.12346.
  • (2015) Ocular angiosarcoma in an American Miniature Horse.Gerding JC, Gilger BC, Clode AB, Montgomery K. | Vet Ophthalmol 015 Nov;18(6):502-9. doi: 10.1111/vop.12249
  • (2015) Modified lamellar keratoplasties for the treatment of deep stromal abscessesMcMullen RJ, Gilger BC, Miller TM. | Vet Ophthalmol 2015 Sep;18(5):393-403. doi: 10.1111/vop.12227.
  • (2015) Evaluation of factors leading to post-anesthetic complications in healthy horses following general anesthesia for ophthalmic and non-ophthalmic proceduresE Curto, LP Posner, KT Walsh, JA Balko, BC Gilger | JAVMA In Review, 8-2015
  • (2015) Causes of endogenous uveitis in cats presented to referral clinics in North Carolina.Jinks MR, English RV, Gilger BC. | Vet Ophthalmol 2015, 10.1111/vop.12324
  • (2015) Retrobulbar pigmented peripheral nerve sheath tumor in a dog.Curto E, Clode AB, Montgomery KW, Gilger BC. | Vet Ophthalmol 2015; 10.1111/vop.12327
  • (2015) Prognosis and impact of equine recurrent uveitis.Gerding JC, Gilger BC. | Equine Veterinary Journal 2015 Apr 18. doi: 10.1111/evj.12451).
  • (2015) Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery.Cholkar K, Gilger BC, Mitra AK. | Translational Vision Science and Technology 2015;4(3) DOI: 10.1167/tvst.4.3.1.
  • (2014) Use of episcleral cyclosporine implants in dogs with keratoconjunctivitis sicca.Barachetti L, Rampazzo A, Mortellaro, CM, Scevola S, Gilger BC | Vet Ophthalmol 2014 (DOI:10.1111/vop.12173).
  • (2014) Episcleral, intrascleral, and suprachoroidal routes of ocular drug delivery – Recent research advances and patents.Gilger BC, Mandal A, Shah S, Mitra AK. | Recent Patents on Drug Delivery and Formulation 2014 (DOI:10.2174/187221130802150707093509).
  • (2014) Heterochromic iridocyclitis with secondary keratitis (HIK) in adult horses: Clinical, histopathological and immunohistochemical characterization.Pinto NI, McMullen RJ, Linder KE, Cullen JM, Gilger BC. | Vet Ophthalmol 2014 (DOI:10.1111/vop.12234).
  • (2014) Spectral-domain optical coherence tomography (SD-OCT) evaluation of the cornea, retina, and optic nerve in normal horsesPinto NI, Gilger BC. | Vet Ophthalmol 2014 (DOI:10.1111/vop.12180)
  • (2014) Retrospective analysis of equine cataract surgery – visual outcomes vs age, IOL, and ERU status (35 cases).Edelmann ML, Clode AB, Gilger BC. | Vet Ophthalmol 2014 (DOI:10.1111/vop.12185).